Results 161 to 170 of about 183,958 (171)

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Lancet, The, 2019
Denis Soulieres, Christophe Le Tourneau, Lisa F Licitra   +2 more
exaly  

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, Omid Hamid   +2 more
exaly  

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Lancet, The, 2016
Roy S Herbst, Paul Baas, Dong-Wan Kim
exaly  

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Lancet Oncology, The, 2018
Andrew X Zhu, Richard S Finn, Julien Edeline   +2 more
exaly  

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2016
Martin Reck, Delvys Rodriguez-Abreu, Rina Hui   +2 more
exaly  

Pembrolizumab

Reactions Weekly, 2018
openaire   +1 more source

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Lancet, The, 2019
Kevin J Harrington, Richard F Greil, Denis Soulieres   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2018
Leena Gandhi, Delvys Rodriguez-Abreu, Shirish Gadgeel   +2 more
exaly  

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Lancet, The
exaly